Document Type : Original Articles


1 Physical Therapy Department, School of Rehabilitation Sciences, Tehran University of Medical Sciences, Tehran, Iran

2 Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran.

3 Rehabilitation Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran



Background: Sub acromial pain syndrome (SAPS) is one of the most common complaints of shoulder pain and long lasting disability without treatment or accessibility to the rehabilitation center. Treatment of musculoskeletal shoulder pain is challenging, so evidence suggest that exercise therapy(ET) plus manual therapy(MT) can be a good choice for healing shoulder dysfunctions. For treatment at the best time without the pain becoming chronic it seems that, tele-physical therapy is an effective method to deliver ET and MT properly.
Method: A prospective, assessor blind, randomized controlled clinical trial will be designed to include 33 patients with SAPS that will divide them into three groups (11 participants in each groups): “Control group (supervised ET+ MT)”, “videoconferencing group (ET+ self-release therapy)” and “video based group (ET+ self-release therapy)”. Self-releases include self-joint mobilization+ self-myofascial release with tennis ball.  MT include joint mobilization techniques and transverse friction massages. ET consist of stretching and strengthening exercises. Each patient in 3 groups will receive 10 sessions of ET and MT during 3 weeks of interventions.  Assessments will be done in 3 times (baseline, midterm and post treatment). Pain by Visual Analogue Scale, function by Shoulder Pain and Disability Index, Range of Motion, Telehealth Satisfaction Scale and Physical Therapy Patient Satisfaction Questionnaire will be assessed.
Discussion: This trial will focus on assessment of tele physical therapy based on ET and myofascial release in comparison to face to face approach with supervised ET and MT on pain, function, Range of Motion and patient satisfaction.
Trial registration: This trial is registered in the Iranian Registry of Clinical Trials (IRCT)
( IRCT20220622055252N1, on December 29, 2022)